ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

DCE Advisors Approve New Grant Program On Lung Carcinoma

June 30, 1995

Price Increase

July 22, 1983

Mihich Subcommittee Recommendations For Augmenting Agents In BRMP Described

December 7, 1979

Waxman Adds NIH Bypass Budget To Authorization Bill, OKs$1.32 Billion for NCI In FY 1984

April 1, 1983

Generic Paclitaxel Approval Withstands Court Challenge.

May 4, 2001

House Figures for NCI, NIH Will Be Known This Week; Senate Probably Will Wait Until After Recess

July 31, 1987